<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04872218</url>
  </required_header>
  <id_info>
    <org_study_id>CITO-2021-01</org_study_id>
    <nct_id>NCT04872218</nct_id>
  </id_info>
  <brief_title>Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy</brief_title>
  <acronym>ATARI</acronym>
  <official_title>A Double-blind Randomized Controlled Trial of 6-month of Abatacept vs Placebo as Adjuvant to Peanut Oral Immunotherapy to Induce Immunologic Changes in Patients With Severe Persistent Peanut Allergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philippe Bégin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Justine's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2a, multi-center, randomized and double-blind placebo-controlled trial&#xD;
      comparing 24 weeks of abatacept versus placebo used as adjuvant to oral immunotherapy to&#xD;
      induce remission in adolescents and adults with persistent severe peanut allergy.&#xD;
&#xD;
      This is a proof-of-concept trial in which the primary outcome will be the suppression of the&#xD;
      initial peanut specific IgE surge during OIT, which is used as a proxy outcome of peanut&#xD;
      allergy remission.&#xD;
&#xD;
      Adolescents and adults with persistent severe peanut allergy (n=14) will be randomized to&#xD;
      either abatacept or placebo at a ratio 1:1 for a total period of 24 weeks. Peanut oral&#xD;
      immunotherapy will be initiated the day following the first administration of the&#xD;
      investigational product. Sustained tolerance to peanut will be assessed at 36 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peanut specific/total IgE at week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Relative change in peanut specific/total IgE from baseline to week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peanut-specific IgG4/IgE ratio at week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Relative change in peanut-specific IgG4/IgE ratio from baseline to week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peanut-specific IgG4 at week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Absolute change in peanut-specific IgG4 from baseline to week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained tolerance</measure>
    <time_frame>Assessed between week 36 and week 48</time_frame>
    <description>Maximum period of avoidance after which a oral food challenge with 300 mg peanut protein is still tolerated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food dosing reactions</measure>
    <time_frame>48 weeks</time_frame>
    <description>Mean cumulative function of food dosing allergic reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desensitization</measure>
    <time_frame>36 weeks</time_frame>
    <description>Highest tolerated dose on an oral food challenge at week 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desensitization speed</measure>
    <time_frame>36 weeks</time_frame>
    <description>Time from the onset of oral immunotherapy to the maintenance dose of 300mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>48 weeks</time_frame>
    <description>Overall rate of adverse events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Atopy patch test</measure>
    <time_frame>week 12, week 24 and week 48</time_frame>
    <description>Change in peanut atopy patch test from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Skin test</measure>
    <time_frame>week 12, week 24 and week 48</time_frame>
    <description>Change in peanut skin test from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Peanut specific/total IgE, other time points</measure>
    <time_frame>weeks 2, 6, 12, 36 and 48</time_frame>
    <description>Relative change in peanut specific/total IgE from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Peanut-specific IgG4/IgE ratio, other time points</measure>
    <time_frame>weeks 2, 6, 12, 36 and 48</time_frame>
    <description>Relative change in peanut-specific IgG4/IgE ratio from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Peanut-specific IgG4, other time points</measure>
    <time_frame>weeks 2, 6, 12, 36 and 48</time_frame>
    <description>Absolute change from baseline in peanut-specific IgG4</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Peanut Allergy</condition>
  <arm_group>
    <arm_group_label>Abatacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>24 week treatment of IV abatacept following recommended dosages from the monograph</description>
    <arm_group_label>Abatacept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>24 week treatment of IV placebo following recommended dosages from the abatacept monograph</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Peanut oral immunotherapy</intervention_name>
    <description>Peanut oral immunotherapy, following a patient-driven protocol, starting 24 to 72h after the first administration of abatacept or placebo.</description>
    <arm_group_label>Abatacept</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects 14 to 50 years old at screening visit&#xD;
&#xD;
          -  History of IgE mediated allergy to peanut protein&#xD;
&#xD;
          -  ImmunoCAP IgE level &gt; 50 kU/L for peanut;&#xD;
&#xD;
          -  Total IgE level &lt; 5000 kU/L&#xD;
&#xD;
          -  Willing to comply to all study requirements during participation in the study;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous adverse reactions to abatacept;&#xD;
&#xD;
          -  Known hypersensitivity to abatacept or any of its components;&#xD;
&#xD;
          -  Patients at risk of sepsis, such as immunocompromised or HIV positive;&#xD;
&#xD;
          -  Patient undergoing a treatment with any other biologic agent;&#xD;
&#xD;
          -  Uncontrolled asthma;&#xD;
&#xD;
          -  Unstable angina, significant arrhythmia, uncontrolled hypertension, chronic sinusitis,&#xD;
             or other chronic or immunological diseases that, in the judgment of the investigator,&#xD;
             might interfere with the evaluation, administration of the test drug or pose&#xD;
             additional risk to the subject (e.g., gastrointestinal or gastroesophageal disease,&#xD;
             chronic infections, scleroderma, hepatic and gallbladder disease, chronic non-allergic&#xD;
             pulmonary disease);&#xD;
&#xD;
          -  Current users of oral, intramuscular, or intravenous corticosteroids, tricyclic&#xD;
             antidepressants or beta-blocker&#xD;
&#xD;
          -  Concurrent/prior use of immunomodulatory therapy (within 6 months);&#xD;
&#xD;
          -  A diagnosis of eosinophilic esophagitis, eosinophilic colitis, or eosinophilic&#xD;
             gastritis;&#xD;
&#xD;
          -  Pregnant or breastfeeding women;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>St. Justine's Hospital</investigator_affiliation>
    <investigator_full_name>Philippe Bégin</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Peanut allergy</keyword>
  <keyword>Abatacept</keyword>
  <keyword>Oral immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

